MET and neoplasm: In conclusion, our results clearly demonstrated that TAS-115 markedly inhibited tumor growth via VEGFR-kinase blockade, and also suppressed bone destruction, possibly through VEGFRs/MET/FMS-kinase blockade, which resulted in potent efficacy of TAS-115 in the A549-Luc-BM1 bone disease model.